Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials

Officials cited data showing the new Alzheimer’s drug has serious safety risks and may not help patients.Officials cited data showing the new Alzheimer’s drug has serious safety risks and may not help patients.Drugs (Pharmaceuticals), Clinical Trials, Aduhelm (Drug), Medicare, Alzheimer’s Disease, Health Insurance and Managed Care, Alzheimer’s Assn, Biogen Inc, Centers for Medicare and Medicaid Services, Food and Drug AdministrationRead More

Leave a Reply

Your email address will not be published.